TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

被引：5
|
作者：
Carter, Bing Z. [1 ]
Yee, Po [1 ]
Kornblau, Steven M. [1 ,2 ]
Tao, Wenjing [1 ]
Nishida, Yuki [1 ]
Ruvolo, Vivian [1 ]
Cidado, Justin [3 ]
Drew, Lisa [4 ]
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Houston, TX 77030 USA
[3] AstraZeneca, Oncol R&D, Waltham, MA USA
[4] AstraZeneca, Oncol IMED Biotech Unit, Waltham, MA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124826
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1271
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics
    Carter, Bing Z.
    Mak, Po Yee
    Tao, Wenjing
    Ostermann, Lauren B.
    Boettcher, Steffen
    Nishida, Yuki
    Ayoub, Edward
    Ruvolo, Vivian
    Jabbour, Elias J.
    Hughes, Paul
    Morrow, P. K.
    Andreeff, Michael
    BLOOD, 2021, 138
  • [2] Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
    Bing Z. Carter
    Po Yee Mak
    Wenjing Tao
    Edward Ayoub
    Lauren B. Ostermann
    Xuelin Huang
    Sanam Loghavi
    Steffen Boettcher
    Yuki Nishida
    Vivian Ruvolo
    Paul E. Hughes
    Phuong K. Morrow
    Torsten Haferlach
    Steven Kornblau
    Muharrem Muftuoglu
    Michael Andreeff
    Blood Cancer Journal, 13
  • [3] Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics (vol 13, 57, 2023)
    Carter, Bing Z.
    Mak, Po Yee
    Tao, Wenjing
    Ayoub, Edward
    Ostermann, Lauren B.
    Huang, Xuelin
    Loghavi, Sanam
    Boettcher, Steffen
    Nishida, Yuki
    Ruvolo, Vivian
    Hughes, Paul E.
    Morrow, Phuong K.
    Haferlach, Torsten
    Kornblau, Steven
    Muftuoglu, Muharrem
    Andreeff, Michael
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [4] Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating AgentResistant and TP53 Mutated AML
    Carter, Bing Z.
    Mak, Po Yee
    Tao, Wenjing
    Ruvolo, Vivian
    Zhang, Xuan
    Nishida, Yuki
    Kornblau, Steven M.
    Hughes, Paul
    Chen, Xiaoyue
    Morrow, P. K.
    Andreeff, Michael
    BLOOD, 2020, 136
  • [5] BH3 PROFILING IDENTIFIES BCL-2 AND MCL-1 DEPENDENCIES IN LYMPHOPLASMACYTIC LYMPHOMA
    Frusteri, C.
    Paluzzi, M.
    Lovato, E.
    Ferrarini, I.
    HAEMATOLOGICA, 2024, 109 : 92 - 92
  • [6] Most putative BH3 mimetics preferentially antagonize the anti-apoptotic protein MCL-1 rather than BCL-2
    Albershardt, Tina C.
    Pletnev, Alexandre A.
    Eastman, Alan
    CANCER RESEARCH, 2010, 70
  • [7] Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition
    Song, Ting
    Chai, Gaobo
    Liu, Yubo
    Xie, Mingzhou
    Chen, Qingbin
    Yu, Xiaoyan
    Sheng, Hongkun
    Zhang, Zhichao
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 70 : 64 - 71
  • [8] Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
    Dalafave, D. S.
    Prisco, G.
    CANCER INFORMATICS, 2010, 9 : 169 - 177
  • [9] Targeting the Bcl-2/BH3 protein-protein interaction: Identification, design, and synthesis of new selective inhibitors of the Mcl-1/BH3 interaction
    Pernazza, Daniele
    Lawrence, Harshani R.
    Doi, Kenichiro
    Sung, Shen-Shu
    Guida, Wayne C.
    Sebti, Said M.
    Wang, Hong-Gang
    Lawrence, Nicholas J.
    CANCER RESEARCH, 2010, 70
  • [10] Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations
    Henz, Kristina
    Al-Zebeeby, Aoula
    Basoglu, Marion
    Fulda, Simone
    Cohen, Gerald M.
    Varadarajan, Shankar
    Vogler, Meike
    BIOLOGICAL CHEMISTRY, 2019, 400 (02) : 181 - 185
12345